Oro-mucosal midazolam maleate: Use and effectiveness in adults with epilepsy in the UK

Journal article


Shankar, Rohit, Goodwin, Melesina, Toland, John, Boyle, Andrew, Grant, A., Pearson, Josephine, Storer, Amanda, Higgins, Richard, Hudson, Sharon and Reuber, Markus 2021. Oro-mucosal midazolam maleate: Use and effectiveness in adults with epilepsy in the UK. Epilepsy & Behavior. 123, pp. 1-4. https://doi.org/10.1016/j.yebeh.2021.108242
AuthorsShankar, Rohit, Goodwin, Melesina, Toland, John, Boyle, Andrew, Grant, A., Pearson, Josephine, Storer, Amanda, Higgins, Richard, Hudson, Sharon and Reuber, Markus
Abstract

Oro-mucosal midazolam maleate (OMM) with suitable training to family and carers is being increasingly recognized as the treatment of choice to mitigate the development of status epilepticus in non-hospital community settings. There are no studies to describe the use, effectiveness, and suitable dosing of OMM in adults with epilepsy in community settings. To describe the use, effectiveness, and dosing of OMM in the emergency treatment of epileptic seizures in community settings. A retrospective observational study (2016–17) design was used with participant recruitment from four UK NHS secondary care outpatient clinics providing epilepsy management. Study sample was of adult people with epilepsy (PWE) having had a recent seizure requiring OMM. Data on patient demographics, patient care plans, details of a recent seizure requiring emergency medication, and dose of OMM were collected from medical records. Study data from 146 PWE were included. The mean age of PWE was 41.0 years (SD 15.2) and mean weight was 64.8Kg (SD 18.2). Fifty-three percent of PWE were recorded as having intellectual disability. The most frequently used concomitant medications were lamotrigine (43%). The majority of seizures occurred at people’s homes (n = 92, 63%). OMM was most often administered by family/professional care-givers (n = 75, 48.4%). Generalized (tonic/clonic) seizures were recorded in most people (n = 106, 72.6%). The most common initial dose of OMM was 10 mg (n = 124, 84.9%). The mean time to seizure cessation after administration of this initial dose was 5.5 minutes (SD = 4.5, Median 5.0, IQR 2.1–5.0). Only a minority of seizures led to ambulance callouts (n = 18, 12.3%) or hospital admissions (n = 13, 9%). This is the first observational study describing the use and effectiveness of OMM in adults in community settings. Minimal hospital admissions were reported in this cohort and the treatment was effective in ending seizures in adults in community settings.

KeywordsBuccal midazolam; Rescue medication; Community prevention of status; Epilepsy safety; Intellectual disabilities
Year2021
JournalEpilepsy & Behavior
Journal citation123, pp. 1-4
PublisherElsevier
ISSN1525-5050
Digital Object Identifier (DOI)https://doi.org/10.1016/j.yebeh.2021.108242
Web address (URL)hdl:10545/625998
https://www.sciencedirect.com/science/article/pii/S1525505021005035#!
https://eprints.whiterose.ac.uk/177073/
Output statusPublished
Publication dates07 Aug 2021
Publication process dates
Deposited15 Sep 2021, 08:59
Accepted24 Jul 2021
ContributorsUniversity of Plymouth Medical School, Cornwall Partnership, NHS Foundation Trust, Northampton General Hospital, NHS Trust, NHS Fife, NHS Lothian, University of Derby, Sheffield Teaching Hospitals, NHS Foundation Trust and University of Sheffield
File
File Access Level
Restricted
Permalink -

https://repository.derby.ac.uk/item/9226q/oro-mucosal-midazolam-maleate-use-and-effectiveness-in-adults-with-epilepsy-in-the-uk

  • 36
    total views
  • 0
    total downloads
  • 1
    views this month
  • 0
    downloads this month

Export as

Related outputs

Reducing the Risk of Drowning in the Bath for People with Epilepsy through product Development
Collier, E., Garner, D., Grant, A. and Hayes, K. 2024. Reducing the Risk of Drowning in the Bath for People with Epilepsy through product Development. British Journal of Neuroscience Nursing. 20 (3), pp. 86-92. https://doi.org/10.12968/bjnn.2024.0001